This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Dividendos de Karo Pharma

Dividendo controles de criterios 0/6

Información clave

Rentabilidad por dividendo

Ratio de pago

Rentabilidad media de la industria	2.3%
Próxima fecha de pago de dividendos	n/a
Fecha ex dividendo	n/a
Dividendo por acción	n/a
Beneficios por acción	-SEK 0.69
Previsión de rentabilidad por dividendo	n/a

Últimas actualizaciones de dividendos

No hay actualizaciones

Recent updates

Estabilidad y crecimiento de los pagos

Obteniendo datos sobre dividendos

Dividendo estable: Insufficient data to determine if KARO's dividends per share have been stable in the past.

Dividendo creciente: Insufficient data to determine if KARO's dividend payments have been increasing.

Rentabilidad por dividendo vs. Mercado

Rentabilidad por dividendo de Karo Pharma vs. Mercado

¿Cómo se compara la rentabilidad por dividendo de KARO con la del mercado?
Segmento	Rentabilidad por dividendo
Empresa (KARO)	0%
Suelo de mercado 25% (SE)	1.5%
Techo de mercado 25% (SE)	4.3%
Media de la industria (Pharmaceuticals)	2.3%
Analista de previsiones (KARO) (hasta 3 años)	n/a

Dividendo destacado: Unable to evaluate KARO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

Alto dividendo: Unable to evaluate KARO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Pago de beneficios a los accionistas

Cobertura de los beneficios: KARO is not paying a notable dividend for the Swedish market.

Pago en efectivo a los accionistas

Cobertura de flujo de caja: Unable to calculate sustainability of dividends as KARO has not reported any payouts.

This company listing is no longer active

Dividendos de Karo Pharma

Dividendo controles de criterios 0/6

Información clave

Últimas actualizaciones de dividendos

Recent updates

Nasdaq Approves Karo Pharma's Application for De-Listing

Karo Intressenter AB made a public cash offer to acquire remaining 13.6% stake in Karo Pharma AB (publ) (OM : KARO) for SEK 2.2 billion.

Karo Pharma AB (publ) (OM:KARO) completed the acquisition of E45 brand and related sub-brands from Reckitt Benckiser Group plc (LSE:RKT).

Karo Pharma AB (publ) to Report Fiscal Year 2021 Final Results on Apr 12, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

Karo Pharma AB (publ) to Report Nine Months, 2022 Results on Oct 25, 2022

Karo Pharma AB (publ) to Report Fiscal Year 2021 Results on Feb 25, 2022

Karo Pharma AB (publ) completed the acquisition of Sylphar N.V. from Vendis Capital Management, Robin List, Sylphar's founder and others.

Karo Pharma AB (publ) entered into an agreement to acquire Sylphar N.V. from Vendis Capital Management, Robin List, Sylphar's founder and others for €300 million.

Third quarter 2021 earnings released: EPS kr0.26 (vs kr0.013 loss in 3Q 2020)

Karo Pharma (STO:KARO) Has No Shortage Of Debt

Second quarter 2021 earnings released: kr0.095 loss per share (vs kr0.11 profit in 2Q 2020)

Is Karo Pharma (STO:KARO) A Risky Investment?

Evolan Pharma AB acquired Portfolio Consisting of 12 Brands from Karo Pharma AB (publ) (OM:KARO).

Independent Chairman of the Board Bo Hansen has left the company

First quarter 2021 earnings released: EPS kr0.24 (vs kr0.39 in 1Q 2020)

Full year 2020 earnings released: EPS kr0.37 (vs kr0.051 in FY 2019)

Karo Pharma (STO:KARO) Seems To Be Using A Lot Of Debt

Karo Pharma's (STO:KARO) Strong Earnings Are Of Good Quality

Is Karo Pharma AB (publ)'s (STO:KARO) 1.5% ROE Worse Than Average?

Full year 2020 earnings released: EPS kr0.37 (vs kr0.051 in FY 2019)

Karo Pharma AB (publ), Annual General Meeting, Apr 21, 2021

Karo Pharma AB (publ) (OM:KARO) acquired European OTC brand portfolio of Teva Pharmaceutical Industries Limited (NYSE:TEVA) for €84 million.

Did You Participate In Any Of Karo Pharma's (STO:KARO) Fantastic 144% Return ?

New 90-day low: kr48.85

New 90-day low: kr51.10

Karo Pharma AB (publ) to Report First Half, 2021 Results on Jul 22, 2021

New 90-day low: kr58.10

New 90-day low: kr61.10

J2L Holding AB agreed to acquire Swereco AB from Karo Pharma AB (publ) (OM:KARO) for SEK 150 million.

Third quarter earnings released

EQT VIII, a fund managed by EQT Partners completed the acquisition of 66.5% stake in Karo Pharma AB (publ) (OM:KARO) for SEK 4.1 billion.

Karo Pharma AB (publ) (OM:KARO) acquired remaining Pevaryl® brand portfolio from Cilag GmbH International for €58 million.

Karo Pharma AB (publ) to Report Fiscal Year 2020 Results on Feb 18, 2021

Estabilidad y crecimiento de los pagos

Rentabilidad por dividendo vs. Mercado

Pago de beneficios a los accionistas

Pago en efectivo a los accionistas

Descubre empresas que pagan buenos dividendos